Cencora’s third quarter results outperformed Wall Street’s expectations on both revenue and adjusted profit, but the market ...

Cencora delivered strong quarterly results and guidance upgrades, but expectations need to be moderated as these results ...

Cencora COR saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 70 to 78. Please watch ...

Cardinal's pharmaceutical and specialty solutions segment distributes branded, generic, and specialty drugs and over-the-counter healthcare and consumer products. Cardinal plays a central role in the ...

TD Cowen analyst Charles Rhyee maintained a Buy rating on Cencora today and set a price target of $350.00. The company’s shares closed yesterday at $283.78. Elevate Your Investi ...

Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that can do all three for many years are often the ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Cardinal Health. If we consider the specifics of each trade, it is accurate to state that 60% of the investors opened ...

Detailed price information for Dentsply Sirona Inc (XRAY-Q) from The Globe and Mail including charting and trades.

Major indices were in the green at the opening bell on Tuesday as traders digested last month's consumer price index.